WO2002075302A8 - Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal - Google Patents

Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal

Info

Publication number
WO2002075302A8
WO2002075302A8 PCT/US2002/007555 US0207555W WO02075302A8 WO 2002075302 A8 WO2002075302 A8 WO 2002075302A8 US 0207555 W US0207555 W US 0207555W WO 02075302 A8 WO02075302 A8 WO 02075302A8
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cardiopathology
types
offspring
clinically recognized
Prior art date
Application number
PCT/US2002/007555
Other languages
French (fr)
Other versions
WO2002075302A1 (en
Inventor
Yong-Fu Xiao
James P Morgan
Original Assignee
Yong-Fu Xiao
James P Morgan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yong-Fu Xiao, James P Morgan filed Critical Yong-Fu Xiao
Priority to JP2002573666A priority Critical patent/JP2004532202A/en
Priority to EP02753613A priority patent/EP1379869A4/en
Priority to CA002441289A priority patent/CA2441289A1/en
Publication of WO2002075302A1 publication Critical patent/WO2002075302A1/en
Priority to US10/438,574 priority patent/US20040071665A1/en
Publication of WO2002075302A8 publication Critical patent/WO2002075302A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Environmental Sciences (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides therapeutic methods which employ one or more identifiable types of mammalian stem cells, and/or their progenitor progeny cells, and/or their lineage-committed descendant cells, and/or their partially-differentiated offspring cells - with or without completely differentiated cells to treat living mammalian subjects afflicted with a clinically recognized form of cardiopathology. The identifiable cell types include embryonic stem cells and their offspring cells; as well as the presently identified types of adult stem cells and their various offspring cells; and also include recently identified alternative cells types which have functional stem cell properties. Among the clinical forms of cardiopathology which can be efficaciously treated using the present therapeutic methods are myocardial infarction, myocarditis, heart failure, and cardiac dysrhythmia.
PCT/US2002/007555 2000-09-05 2002-03-14 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal WO2002075302A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002573666A JP2004532202A (en) 2001-03-15 2002-03-14 Method of therapeutically treating a clinically recognized form of a cardiac condition in a living mammal
EP02753613A EP1379869A4 (en) 2001-03-15 2002-03-14 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
CA002441289A CA2441289A1 (en) 2001-03-15 2002-03-14 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US10/438,574 US20040071665A1 (en) 2000-09-05 2003-05-15 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US27624601P 2001-03-15 2001-03-15
US27624501P 2001-03-15 2001-03-15
US27624401P 2001-03-15 2001-03-15
US27624701P 2001-03-15 2001-03-15
US27617501P 2001-03-15 2001-03-15
US27614701P 2001-03-15 2001-03-15
US27624301P 2001-03-15 2001-03-15
US27614801P 2001-03-15 2001-03-15
US60/276,148 2001-03-15
US60/276,245 2001-03-15
US60/276,175 2001-03-15
US60/276,244 2001-03-15
US60/276,247 2001-03-15
US60/276,147 2001-03-15
US60/276,243 2001-03-15
US60/276,246 2001-03-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/438,574 Continuation US20040071665A1 (en) 2000-09-05 2003-05-15 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal

Publications (2)

Publication Number Publication Date
WO2002075302A1 WO2002075302A1 (en) 2002-09-26
WO2002075302A8 true WO2002075302A8 (en) 2007-09-07

Family

ID=27575321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/007555 WO2002075302A1 (en) 2000-09-05 2002-03-14 Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal

Country Status (4)

Country Link
EP (1) EP1379869A4 (en)
JP (1) JP2004532202A (en)
CA (1) CA2441289A1 (en)
WO (1) WO2002075302A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691216B2 (en) 2001-12-07 2014-04-08 Cytori Therapeutics, Inc. Methods of using regenerative cells to promote wound healing
US8883499B2 (en) 2001-12-07 2014-11-11 Cytori Therapeutics, Inc. Systems and methods for isolating and using clinically safe adipose derived regenerative cells
US9133431B2 (en) 2009-05-01 2015-09-15 Bimini Technologies Llc Systems, methods and compositions for optimizing tissue and cell enriched grafts
US9198937B2 (en) 2001-12-07 2015-12-01 Cytori Therapeutics, Inc. Adipose-derived regenerative cells for treating liver injury
US9463203B2 (en) 2001-12-07 2016-10-11 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of cartilage defects
US9480718B2 (en) 2001-12-07 2016-11-01 Cytori Therapeutics, Inc. Methods of using adipose-derived regenerative cells in the treatment of peripheral vascular disease and related disorders
US9486484B2 (en) 2008-08-19 2016-11-08 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1781371A4 (en) 2004-07-19 2007-12-19 Univ Columbia Assay system for monitoring the effects of genetically engineered cells to alter function of a syncytium
JP5210155B2 (en) * 2005-05-25 2013-06-12 サイトリ セラピューティクス インコーポレイテッド Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
BR112012018771A2 (en) * 2010-01-29 2017-06-20 Metanomics Gmbh '' method for diagnosing heart failure in a subject ''
JP5628131B2 (en) * 2011-10-19 2014-11-19 サイトリ セラピューティクス インコーポレイテッド Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
CA2883890C (en) * 2012-09-12 2021-11-09 Dirk Block Identification of patients with abnormal fractional shortening
US20220323509A1 (en) * 2019-09-05 2022-10-13 Tohoku University Therapeutic agent for myocarditis
CN114176049B (en) * 2022-01-20 2023-01-31 河南农业大学 Method for simultaneously improving bee emergence rate and female worm number of indoor bred cotton bollworm tooth-lipped ichneumon fly

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
AU2001284695A1 (en) * 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2002303343A1 (en) * 2001-04-13 2002-10-28 Anterogen Co., Ltd. Methods and reagents for cell transplantation
AU2002317039B2 (en) * 2001-07-24 2007-10-04 Es Cell International Pte Ltd Methods of inducing differentiation of stem cells

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691216B2 (en) 2001-12-07 2014-04-08 Cytori Therapeutics, Inc. Methods of using regenerative cells to promote wound healing
US8883499B2 (en) 2001-12-07 2014-11-11 Cytori Therapeutics, Inc. Systems and methods for isolating and using clinically safe adipose derived regenerative cells
US9198937B2 (en) 2001-12-07 2015-12-01 Cytori Therapeutics, Inc. Adipose-derived regenerative cells for treating liver injury
US9463203B2 (en) 2001-12-07 2016-10-11 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of cartilage defects
US9480718B2 (en) 2001-12-07 2016-11-01 Cytori Therapeutics, Inc. Methods of using adipose-derived regenerative cells in the treatment of peripheral vascular disease and related disorders
US9492483B2 (en) 2001-12-07 2016-11-15 Cytori Therapeutics, Inc. Methods of using regenerative cells to treat a burn
US9504716B2 (en) 2001-12-07 2016-11-29 Cytori Therapeutics, Inc. Methods of using adipose derived regenerative cells to promote restoration of intevertebral disc
US9511096B2 (en) 2001-12-07 2016-12-06 Cytori Therapeutics, Inc. Methods of using regenerative cells to treat an ischemic wound
US9511094B2 (en) 2001-12-07 2016-12-06 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US9486484B2 (en) 2008-08-19 2016-11-08 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
US9133431B2 (en) 2009-05-01 2015-09-15 Bimini Technologies Llc Systems, methods and compositions for optimizing tissue and cell enriched grafts

Also Published As

Publication number Publication date
EP1379869A1 (en) 2004-01-14
WO2002075302A1 (en) 2002-09-26
CA2441289A1 (en) 2002-09-26
EP1379869A4 (en) 2004-08-11
JP2004532202A (en) 2004-10-21

Similar Documents

Publication Publication Date Title
WO2002075302A8 (en) Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
Fukuda et al. Mesenchymal, but not hematopoietic, stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction in mice
Wallace et al. Histochemical identification of cortical areas in the auditory region of the human brain
Jiang et al. Bone marrow mesenchymal stem cells can improve the motor function of a Huntington's disease rat model
WO2006091895A3 (en) Method for the treatment of retinopathy of prematurity and related retinopathic diseases
PT2730650T (en) Method for processing mesenchymal stem cells and the use thereof in the treatment of diseases associated with oxidative stress
WO2009043159A8 (en) Neural tumor stem cells and methods of use thereof
WO2006121532A3 (en) Treatment for heart disease
ATE394110T1 (en) ISOLATED STROMAL CELLS FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
Jackson et al. Neurotrophin regulation of energy homeostasis in the central nervous system
Ryu et al. Brain transplantation of neural stem cells cotransduced with tyrosine hydroxylase and GTP cyclohydrolase 1 in Parkinsonian rats
KR20180091101A (en) Induced cardiac pacemaker from adult stem cells and furcine cells
EP1807509A4 (en) Multipotent stem cells isolated from umbilical cord blood and the cellular therapeutic agent comprising the same for treating ischemic disease
WO2001021771A3 (en) Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
KR20230010617A (en) Mesenchymal stem cells with oxidative stress resistance, manufacturing method and use thereof
DE60230774D1 (en) INSULATION OF NERVE STEM CELLS USING GANGLIOSIDES AND OTHER SURFACE MARKERS
BR9906926A (en) Compositions and methods for treating cells having double minute dna
CN104548136B (en) A kind of piRNA medical composition and its uses
Rossi et al. Exclusion of the ACE D/I gene polymorphism as a determinant of endothelial dysfunction
CN109266681A (en) A kind of method for building up of " humanized " Short QT syndiome disease model
WO2005094267A3 (en) Methods for regulating differentiation of neural cells and uses thereof
Matteini et al. Rejuvenating aged stem cells: therapeutic strategies to extend health and lifespan
WO2006128885A3 (en) Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
WO2007133572A3 (en) Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure
AU2018297171B2 (en) Compositions and methods for treating or preventing catecholaminergic polymorphic ventricular tachycardia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10438574

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2441289

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002573666

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002306702

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002753613

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002753613

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002753613

Country of ref document: EP